Wyeth CCI-779 Survival Benefit Over Interferon In Kidney Cancer May Warrant First-Line Use
This article was originally published in The Pink Sheet Daily
Executive Summary
CCI-779 (temsirolimus) monotherapy is associated with a 49% improvement in median overall survival compared to interferon in advanced renal cell carcinoma patients.
You may also be interested in...
Wyeth Submits NDA For Temsirolimus In Kidney Cancer
Torisel would be the only renal cell carcinoma drug on the market to offer a significant survival benefit, Wyeth says.
Wyeth Submits NDA For Temsirolimus In Kidney Cancer
Torisel would be the only renal cell carcinoma drug on the market to offer a significant survival benefit, Wyeth says.
Wyeth Will Develop Rapamycin Analogs Under Alliance With Biotica
Deal builds on Wyeth's Rapamune expertise.